JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 卷:110 |
Estimation of the dose of fluticasone propionate inhaled by infants after bronchiolitis: Effect on urinary cortisol excretion | |
Article | |
Wong, J ; Davies, T ; O'Callaghan, C | |
关键词: inhaled steroid; aerosol; Babyhaler; spacer device; aerosol drug delivery; urinary cortisol creatinine ratio; bronchiolitis; infant; | |
DOI : 10.1067/mai.2002.128858 | |
来源: Elsevier | |
【 摘 要 】
Background: Information on the dose of steroid infants inhale from spacer devices and its potential effect on adrenal suppression is limited. Objective: We sought to determine the total dose of fluticasone propionate (FP) inhaled from a spacer device (Babyhaler) with face mask attachment by infants recovering from acute bronchiolitis and the effect of inhaled FP on the infants' overnight urinary cortisol/creatinine ratios (UCCRs). Methods: Infants studied were recovering from acute bronchiolitis. In study 1, 22 infants inhaled 150 mug of FP through the Babyhaler. The likely inhaled dose was estimated by trapping it on a filter held within the face mask. In study 2, 40 infants had UCCRs measured before and during 3 months of treatment with either FP (150 mug twice daily, n = 20) or placebo (n = 20). Results: In study 1 the mean +/- SD dose of captured FP was 12.8 +/- 6.9 mug (ie, 2.1 +/- 1.2 mug/kg). In study 2 the pretreatment UCCR medians (interquartile ranges) were as follows: FP, 22.8 (23.0) nmol/mmol; placebo, 24.0 (28.3) nmol/mmol. Within-group UCCR changes (median and interquartile range DeltaUCCR) were significantly different in the FP group (-8.9 and -20.6 nmol/mmol at 6 weeks and -12.6 and -25.9 nmol/mmol at 12 weeks, respectively; P = .0008) but not in the placebo group (-5.8 and -10.7 nmol/mmol at 6 weeks and +0.3 and -17.9 nmol/mmol at 12 weeks, respectively; P = .45). Intergroup changes were insignificant in the follow-up period (6 weeks, P = .52; 12 weeks, P = .19). Conclusion: After bronchiolitis, infants are likely to inhale approximately 8% of the nominal steroid dose from the Babyhaler. UCCRs can be used to monitor the bioavailability of inhaled steroids in young infants.
【 授权许可】
Free
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
10_1067_mai_2002_128858.pdf | 147KB | download |